Key Market Indicators
Sales of diabetes medicine in Austria are set to reach nearly $287 million by 2026. This is a 2.3% year-on-year increase from the 2021 figure of $252 million. This growth has been steady since 2015, when the market was up 8.7% year-on-year. Austria came 13th in the 2021 rankings, with Hungary taking the lead at $252 million. Canada, Spain and Italy came in positions two, three and four respectively. Imports of insulin to Austria are projected to fall to $37 million by 2026, from $37 million in 2021. This is a 0% year-on-year decrease. However, demand has been rising steadily since 1999, up 1.7% year-on-year. Exports of insulin from Austria increased to $843,000 in 2018, from $835,000 in 2017. This was a 1% increase compared to the previous year. Since 1999, Austrian exports have grown 20.3% year-on-year. Austria was positioned at number 32 in 2018, with Singapore leading the rankings at $843,000. France, Italy and China came in second, third and fourth places respectively.
